Intelligence Profile
Safety Profile
The evidence provided offers limited direct information about dulaglutide's safety profile. The available data comes primarily from study titles and clinical trial listings, with minimal detailed safety information.
Known Side Effects
The evidence provided does not contain comprehensive safety data for dulaglutide specifically. One meta-analysis examining GLP-1 receptor agonist therapy in children and adolescents mentions "differential cardiometabolic efficacy and safety profiles" but does not detail specific adverse events for dulaglutide.
A systematic review assessed "the risk of diabetic retinopathy progression with GLP-1 receptor agonists," suggesting this may be a concern with this drug class, though specific findings for dulaglutide are not detailed in the available evidence.
Special Populations
Hepatic Impairment: One completed Phase 1 study (NCT01253304) specifically examined dulaglutide in subjects with varying degrees of liver impairment, indicating that hepatic function may affect the drug's use, though specific recommendations are not provided in the available evidence.
Pediatric Use: A network meta-analysis examined GLP-1 receptor agonist use in children and adolescents with obesity, suggesting dulaglutide may be used in younger populations, but safety specifics are not detailed.
Contraindications and Drug Interactions
The provided evidence does not contain information about specific contraindications or drug interactions for dulaglutide.
Evidence Limitations
The evidence provided is extremely limited regarding dulaglutide's safety profile. The available information consists mainly of study titles and clinical trial listings without detailed safety outcomes, adverse event rates, or specific contraindications. Most studies focus on efficacy comparisons rather than comprehensive safety assessments.
This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized medical guidance and complete prescribing information.